253 related articles for article (PubMed ID: 29154368)
1. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes.
Mann K; Roos CR; Hoffmann S; Nakovics H; Leménager T; Heinz A; Witkiewitz K
Neuropsychopharmacology; 2018 Mar; 43(4):891-899. PubMed ID: 29154368
[TBL] [Abstract][Full Text] [Related]
2. Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response.
Witkiewitz K; Roos CR; Mann K; Kranzler HR
Alcohol Clin Exp Res; 2019 Nov; 43(11):2395-2405. PubMed ID: 31436886
[TBL] [Abstract][Full Text] [Related]
3. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response.
Votaw VR; Mann K; Kranzler HR; Roos CR; Nakovics H; Witkiewitz K
Drug Alcohol Depend; 2022 Mar; 232():109257. PubMed ID: 35042096
[TBL] [Abstract][Full Text] [Related]
4. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
5. Reward drinking and naltrexone treatment response among young adult heavy drinkers.
Roos CR; Bold KW; Witkiewitz K; Leeman RF; DeMartini KS; Fucito LM; Corbin WR; Mann K; Kranzler HR; O'Malley SS
Addiction; 2021 Sep; 116(9):2360-2371. PubMed ID: 33620746
[TBL] [Abstract][Full Text] [Related]
6. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
[TBL] [Abstract][Full Text] [Related]
7. Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.
Kady A; Grodin EN; Ray LA
Alcohol Alcohol; 2024 May; 59(4):. PubMed ID: 38953743
[TBL] [Abstract][Full Text] [Related]
8. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
9. Targeted naltrexone for problem drinkers.
Kranzler HR; Tennen H; Armeli S; Chan G; Covault J; Arias A; Oncken C
J Clin Psychopharmacol; 2009 Aug; 29(4):350-7. PubMed ID: 19593174
[TBL] [Abstract][Full Text] [Related]
10. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
12. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Fucito LM; Park A; Gulliver SB; Mattson ME; Gueorguieva RV; O'Malley SS
Biol Psychiatry; 2012 Nov; 72(10):832-8. PubMed ID: 22541040
[TBL] [Abstract][Full Text] [Related]
14. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
[TBL] [Abstract][Full Text] [Related]
15. The effects of drinking goal on treatment outcome for alcoholism.
Bujarski S; O'Malley SS; Lunny K; Ray LA
J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
[TBL] [Abstract][Full Text] [Related]
16. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.
Krishnan-Sarin S; Krystal JH; Shi J; Pittman B; O'Malley SS
Biol Psychiatry; 2007 Sep; 62(6):694-7. PubMed ID: 17336941
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
Brünen S; Bekier NK; Hiemke C; Korf F; Wiedemann K; Jahn H; Kiefer F
Alcohol Alcohol; 2019 Jan; 54(1):51-55. PubMed ID: 30260366
[TBL] [Abstract][Full Text] [Related]
19. Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.
Mann K; Vollstädt-Klein S; Reinhard I; Leménager T; Fauth-Bühler M; Hermann D; Hoffmann S; Zimmermann US; Kiefer F; Heinz A; Smolka MN
Alcohol Clin Exp Res; 2014 Nov; 38(11):2754-62. PubMed ID: 25421512
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
